Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Marketing Safety Surveillance Should Include Data Mining Techniques, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The advantages and limitations of data analysis from large adverse event databases are described in a draft guidance. Safety signals found through data mining should be put in the context of total patients exposed to the drug and considered for further investigation, FDA recommends.
Advertisement

Related Content

Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals
Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals
Drug Safety Final Guidances To Be Published In March, FDA Says
Drug Safety Final Guidances To Be Published In March, FDA Says
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency

Topics

Advertisement
UsernamePublicRestriction

Register

PS059576

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel